DOI QR코드

DOI QR Code

Are So-Called Cancer-Testis Genes Expressed Only in Testis?

  • Ghafouri-Fard, Soudeh (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Rezazadeh, Fatemeh (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Zare-Abdollahi, Davood (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Omrani, Mir Davood (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences) ;
  • Movafagh, Abolfazl (Department of Medical Genetics, Shahid Beheshti University of Medical Sciences)
  • Published : 2014.10.11

Abstract

Cancer-testis (CT) antigens are a group of tumor-associated antigens with restricted expression in normal tissues except for testis and expression in a wide variety of tumor tissues. This pattern of expression makes them suitable targets for immunotherapy as well as potential biomarkers for early detection of cancer. However, some genes attributed to this family are now known to be expressed in other normal tissues which put their potential applications in immunotherapy and cancer detection under question. Here we analyzed expression of two previously known CT antigens, RHOXF2 and PIWIL2, in AML patients versus normal donors and found no significant difference in the expression of these genes between the two groups. As these two genes showed expression in normal leukocytes, their expression pattern seems to be wider than to be attributed to the CT gene family. Future research should focus on the expression profiles of so called CT antigens to find those with more testis specific expression.

Keywords

References

  1. Atanackovic D, Luetkens T, Kloth B, et al (2011). Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol, 86, 918-22. https://doi.org/10.1002/ajh.22141
  2. Cen YH, Guo WW, Luo B, et al (2012). Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biol Int, 36, 917-22. https://doi.org/10.1042/CBI20120037
  3. Chan WI, Huntly BJ (2008). Leukemia stem cells in acute myeloid leukemia. Semin Oncol, 35, 326-35. https://doi.org/10.1053/j.seminoncol.2008.04.003
  4. Costello RT, Rey J, Fauriat C, Gastaut JA, Olive D (2003). New approaches in the immunotherapy of haematological malignancies. Eur J Haematol, 70, 333-45. https://doi.org/10.1034/j.1600-0609.2003.00065.x
  5. Ghafouri-Fard S, Abdollahi DZ, Omrani M, Azizi F (2012). shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev, 13, 5865-9. https://doi.org/10.7314/APJCP.2012.13.11.5865
  6. Ghafouri-Fard S, Modarressi MH (2009). Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 12, 395-404.
  7. He G, Chen L, Ye Y, et al (2010). PIWIL2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. Am J Transl Res, 2, 156-69.
  8. Lee JH, Schutte D, Wulf G, et al (2006). Stem-cell protein PIWIL2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet, 15, 201-11.
  9. Lim SH, Zhang Y, Zhang J (2012). Cancer-testis antigens: the current status on antigen regulation and potential clinical use. Am J Blood Res, 2, 29-35.
  10. Liu JJ, Shen R, Chen L, et al (2010). PIWIL2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol, 3, 328-37.
  11. Meklat F, Li Z, Wang Z, et al (2007). Cancer-testis antigens in haematological malignancies. Br J Haematol, 136, 769-76. https://doi.org/10.1111/j.1365-2141.2006.06484.x
  12. Mukda E, Pintaraks K, Sawangpanich R, Wiangnon S, Pakakasama S (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. Asian Pac J Cancer Prev, 12, 1827-31.
  13. Shibata-Minoshima F, Oki T, Doki, N, et al (2012). Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning. Int J Oncol, 40, 93-8.
  14. Ono T, Kurashige T, Harada N, et al (2001). Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci USA, 98, 3282-7. https://doi.org/10.1073/pnas.041625098
  15. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  16. Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5951-8.
  17. Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH (2013). Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol, 30, 368. https://doi.org/10.1007/s12032-012-0368-8
  18. Yin DT, Wang Q, Chen L, et al (2011). Germline stem cell gene PIWIL2 mediates DNA repair through relaxation of chromatin. PLoS One, 6, 27154. https://doi.org/10.1371/journal.pone.0027154
  19. Zou Y, Zhong W (2012). A likely role for a novel PH-domain containing protein, PEPP2, in connecting membrane and cytoskeleton. Biocell, 36, 127-32.

Cited by

  1. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy vol.9, pp.12, 2017, https://doi.org/10.2217/imt-2017-0083
  2. Melanoma: a prototype of cancer-testis antigen-expressing malignancies vol.9, pp.13, 2017, https://doi.org/10.2217/imt-2017-0091